EXACT Sciences Sets New 12-Month High at $17.17 (EXAS)
EXACT Sciences (NASDAQ:EXAS) hit a new 52-week high during mid-day trading on Thursday , Stock Ratings News reports. The company traded as high as $17.17 and last traded at $17.02, with a volume of 560,311 shares trading hands. The stock had previously closed at $16.60.
A number of analysts have recently weighed in on EXAS shares. Analysts at Goldman Sachs initiated coverage on shares of EXACT Sciences in a research note on Wednesday, June 4th. They set a “buy” rating and a $19.00 price target on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of EXACT Sciences from $17.00 to $18.00 in a research note on Wednesday, June 4th. Finally, analysts at Wedbush downgraded shares of EXACT Sciences from an “outperform” rating to a “neutral” rating in a research note on Friday, May 30th. They now have a $14.00 price target on the stock. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $16.91.
The stock’s 50-day moving average is $13.58 and its 200-day moving average is $13.21. The company’s market cap is $1.430 billion.
EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Thursday, May 1st. The company reported ($0.23) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.19) by $0.04. The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.40 million. During the same quarter last year, the company posted ($0.17) earnings per share. EXACT Sciences’s revenue was down 70.0% compared to the same quarter last year. On average, analysts predict that EXACT Sciences will post $-1.05 earnings per share for the current fiscal year.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.